Figure 1 (IMAGE)

Shinshu University

Figure 1

Caption

The EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by lenvatinib.

Credit

KEN-ICHI ITO, SHINSHU UNIVERSITY

Usage Restrictions

Credit must be given to the creator.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.